fenemal "sad" 10 mg/ml injektionsvæske, opløsning
amgros i/s - phenobarbital - injektionsvæske, opløsning - 10 mg/ml
norotic vet. øredråber, suspension
norbrook laboratories ltd. - clotrimazol, dexamethasonacetat, marbofloxacin - øredråber, suspension
paclitaxel "accord" 6 mg/ml koncentrat til infusionsvæske, opløsning
accord healthcare b.v. - paclitaxel - koncentrat til infusionsvæske, opløsning - 6 mg/ml
lenalidomide accord
accord healthcare s.l.u. - lenalidomid - multipelt myelom - immunosuppressiva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, der ikke er berettiget til transplantation. lenalidomid overenskomst i kombination med dexamethason er indiceret til behandling af myelomatose hos voksne patienter, der har modtaget mindst én tidligere behandling. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
aprepitant "stada" 125 mg kapsler, hårde
stada arzneimittel ag - aprepitant - kapsler, hårde - 125 mg
lenalidomid "helm" 2,5 mg kapsler, hårde
helm ag - lenalidomid - kapsler, hårde - 2,5 mg
lenalidomid "helm ag" 2,5 mg kapsler, hårde
helm ag - lenalidomid - kapsler, hårde - 2,5 mg
midolan 2,5 mg kapsler, hårde
helm ag - lenalidomid - kapsler, hårde - 2,5 mg
sarclisa
sanofi winthrop industrie - isatuximab - multipelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
lenalidomide mylan
mylan ireland limited - lenalidomid - multipelt myelom - immunosuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).